ERBB2 and breast cancer: Several studies in human breast cancer have shown that VEGF-A overexpression is present in tumors with aggressive phenotype, such as HER2-positive and TN subtypes [20,21], being associated with poor prognosis and shorter disease-free survival (DFS) and overall survival (OS) [11,16].